GW Pharmaceuticals

GW Pharmaceuticals Limited
Formerly
  • GW Pharmaceuticals Group PLC (2001–2001)
  • GW Pharmaceuticals PLC (2001–2021)[1]
Company typeSubsidiary
Nasdaq: GWPH
IndustryPharmaceutical industry
Founded1998; 26 years ago (1998)
Founder
  • Geoffrey Guy
  • Brian Whittle
HeadquartersCambridge,
United Kingdom
Key people
Justin Gover (CEO)
Products
RevenueIncrease $527 million (2020)
Decrease -$58 million (2020)
Total assetsIncrease $939 million (2020)
Total equityIncrease $741 million (2020)
Number of employees
1,161 (2020)
ParentJazz Pharmaceuticals
Websitegwpharm.co.uk Edit this at Wikidata
Footnotes / references
[2]

GW Pharmaceuticals Limited[1] is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country.[3] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018.[4] It is a subsidiary of Jazz Pharmaceuticals.

  1. ^ a b "GW PHARMACEUTICALS LIMITED overview - Find and update company information - GOV.UK". Companies House. 15 February 2001. Retrieved 3 August 2023.
  2. ^ "GW Pharmaceuticals PLC 2020 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  3. ^ Landau, Elizabeth (21 June 2010). "World's first fully approved cannabis drug on sale in UK". CNN. Archived from the original on 18 May 2012.
  4. ^ Goldschmidt, Debra; Scutti, Susan (25 June 2018). "FDA approves first cannabis-based drug". CNN.